Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Pat. 2009 Aug;19(8):1039-56. doi: 10.1517/13543770903008551.

Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.

Author information

  • 1Infinity Pharmaceuticals, Inc., Cambridge, MA 02139, USA. Martin.Tremblay@infi.com

Abstract

BACKGROUND:

There is increasing evidence suggesting that blocking aberrant Hedgehog (Hh) signaling can be a novel therapeutic avenue for the treatment of cancer. During the past decade, efforts from academic and industrial groups have led to the discovery of a variety of Hh pathway inhibitors.

OBJECTIVE:

This review covers the patent literature related to Hh pathway inhibitors for the treatment of proliferative diseases, regardless of their modes of action.

METHODS:

A comprehensive survey of the patent literature since 1999 is presented.

RESULTS/CONCLUSION:

Most reported Hh pathway inhibitors act on the key signaling transducer Smoothened (SMO). Screening of compound libraries using reporter and binding assays have identified a broad diversity of chemical structures that interact with SMO. These screening approaches, followed by conventional medicinal chemistry, have delivered important clinical drug candidates, such as GDC-0449 and XL-139. In addition, modification of the naturally occurring Veratrum alkaloid cyclopamine has resulted in various active analogues, including clinical drug candidate IPI-926. Although there are recent scientific literature reports of small molecules acting downstream of SMO, there is limited patent literature on this mode of Hh pathway inhibition.

PMID:
19505195
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk